In summary, we demonstrated that simultaneous tumor-targeted inhibition of mTOR (with Everolimus) and VEGF/NRP1 axis (with EG00229) with the help of a tumor-targeting liposomal formulation was able to induce remarkable inhibition of tumor growth in two different ccRCC xenografts and in a highly aggressive syngeneic mouse model of kidney cancer. This evidence concerns the gene MTOR and kidney cancer.